Furthermore, similar sensitization of cancer cells to other DNA-damaging chemotherapeutic agents through HMGB3 depletion has been observed in other cancer types [31,32,33,34], and HMGB3 has been shown to be a potential biomarker for a variety of cancers, where high expression of HMGB3 is associated with poor patient prognosis [35]. This evidence concerns the gene HMGB3 and cancer.